<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38112944</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2284-0729</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>6 Suppl</Issue><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>European review for medical and pharmacological sciences</Title><ISOAbbreviation>Eur Rev Med Pharmacol Sci</ISOAbbreviation></Journal><ArticleTitle>Presence of viral spike protein and vaccinal spike protein in the blood serum of patients with long-COVID syndrome.</ArticleTitle><Pagination><StartPage>13</StartPage><EndPage>19</EndPage><MedlinePgn>13-19</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.26355/eurrev_202312_34685</ELocationID><ELocationID EIdType="pii" ValidYN="Y">34685</ELocationID><Abstract><AbstractText Label="OBJECTIVE">COVID-19 patients experience, in 10-20% of the cases, a prolonged long-COVID syndrome, defined as the persistence of symptoms for at least two months after the infection. The underlying biological mechanisms of this syndrome remain poorly understood. Several hypotheses have been proposed, among which are the potential autoimmunity resulting from molecular mimicry between viral spike protein and human proteins, the reservoir and viral reproduction hypothesis, and the viral integration hypothesis. Although official data state that vaccinal spike protein is harmless and remains at the site of infection, several studies proposed spike protein toxicity and found it in blood circulation several months after the vaccination. To search for the presence of viral and vaccine spike protein in a cohort of long-COVID patients.</AbstractText><AbstractText Label="PATIENTS AND METHODS">In this study, we employed a proteomic-based approach utilizing mass spectrometry to analyze the serum of 81 patients with long-COVID syndrome. Moreover, viral integration in patients' leukocytes was assessed with a preliminary study, without further investigation.</AbstractText><AbstractText Label="RESULTS">We identified the presence of the viral spike protein in one patient after infection clearance and negativity of COVID-19 test and the vaccine spike protein in two patients two months after the vaccination.</AbstractText><AbstractText Label="CONCLUSIONS">This study, in agreement with other published investigations, demonstrates that both natural and vaccine spike protein may still be present in long-COVID patients, thus supporting the existence of a possible mechanism that causes the persistence of spike protein in the human body for much longer than predicted by early studies. According to these results, all patients with long-COVID syndrome should be analyzed for the presence of vaccinal and viral spike protein.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dhuli</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>MAGI'S LAB, Rovereto, Trento, Italy. kristjana.dhuli@assomagi.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medori</LastName><ForeName>M C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Micheletti</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Donato</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Fioretti</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Calzoni</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Praderio</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>De Angelis</LastName><ForeName>M G</ForeName><Initials>MG</Initials></Author><Author ValidYN="Y"><LastName>Arabia</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Cristoni</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Nodari</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bertelli</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016441">Retracted Publication</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Eur Rev Med Pharmacol Sci</MedlineTA><NlmUniqueID>9717360</NlmUniqueID><ISSNLinking>1128-3602</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ExpressionOfConcernIn"><RefSource>Eur Rev Med Pharmacol Sci. 2024 Jan;28(2):445. doi: 10.26355/eurrev_202401_35160</RefSource><PMID Version="1">38305629</PMID></CommentsCorrections><CommentsCorrections RefType="RetractionIn"><RefSource>Eur Rev Med Pharmacol Sci. 2024 Mar;28(6):2625. doi: 10.26355/eurrev_202403_35774</RefSource><PMID Version="1">38567621</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044967" MajorTopicYN="N">Serum</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="Y">Vaccines</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>19</Day><Hour>19</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>19</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38112944</ArticleId><ArticleId IdType="doi">10.26355/eurrev_202312_34685</ArticleId><ArticleId IdType="pii">34685</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>